Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement
Advertisement
Affitech AS and XOMA Ltd. announced that they have signed an antibody collaboration and crosslicense agreement for antibody-related technologies. Financial terms were not disclosed. Under the agreement, Affitech receives a license to use XOMA's bacterial cell Expression (BCE) technology for developing antibody products using Affitech's phagemid display-based Breitling antibody libraries, CBAS(TM) technology and the AffiScreen(TM) high-throughput screening system. Affitech also receives an option for the production of antibodies under XOMA's intellectual property.
The agreement allows XOMA to use Affitech's naïve antibody library for target research and discovery purposes as well as the development and commercialization of selected antibodies. In addition, Affitech has agreed to build patient-derived libraries for XOMA and discover new antibodies against XOMA targets exploiting Affitech's patient libraries, AffiscreeN(TM) system and its leading edge C.B.A.S.(TM)(Cell-Based Antibody Screening) technology.
The agreement also provides for a release of Affitech and designated collaborators from any past activities using XOMA's antibody expression technology, and allows Affitech to use the XOMA technology in combination with its own technologies in future collaborations.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous